Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAGA-9001a
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VAGA-9001a is a recombinant respiratory syncytial virus (RSV) fusion (F) glycoprotein antigen. It serves as the primary antigenic component of the investigational vaccine VN-0200, developed by VLP Therapeutics. The antigen is designed to trigger the production of neutralizing antibodies and cellular immune responses against both RSV subgroup A and subgroup B. In clinical development, VAGA-9001a is combined with a novel $\beta$-glucan-CpG adjuvant (MABH-9002b) to enhance the immune response in older adults, a population at high risk for severe RSV-related complications. Phase 2 clinical trials in Japanese healthy participants aged 60 to 80 years have demonstrated that the vaccine is well tolerated and elicits significant increases in anti-RSV neutralization activity.
- Other names
- RSV F glycoproteinRSV F protein
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on VAGA-9001a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAGA-9001a.